ClinicalTrials.gg
RecruitingNCT05611697Updated May 18, 2026

Laparoscopic Single Anastomosis Sleeve Ileal Bypass Versus Laparoscopic Sleeve Gastrectomy for Morbid Obesity

An interventional study of Single anastomosis sleeve ileal bypass and Sleeve gastrectomy in Obesity, Morbid, sponsored by Oslo University Hospital. Recruiting at 2 sites in Norway. Open to participants aged 20 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-05-18.

Sponsored by Oslo University Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2023; still recruiting 3 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
220
Allocation
Randomized
Ages
20 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 51 studies in Obesity, Morbid with a site in Norway — 22 open to participants now, 26 under way, none of them phase 3. Obesity, Morbid · Norway.

Planned enrollment
2nd of 21
220 · median 69
Started
2023
the only one that year
No phase
18 of 51
1 open now
Primary completion
2028-12
later than 24 of 25 live
Registered
51st of 51
by date
Lead sponsor
4 of 51
Oslo University Hospital

Among the 51 studies in Obesity, Morbid with a site in Norway, this one is the 2nd largest by planned enrollment of the 21 interventional ones that give a count, is the only one that started in 2023, is one of 18 with no phase, reaches primary completion later than 24 of the 25 other live ones, and was the 51st registered.

Obesity, Morbid

941 studies on the registry are indexed under Obesity, Morbid; 162 are open to participants now.

Browse Obesity, Morbid studies →

Open to participants now

22 of the 51 studies in Obesity, Morbid with a site in Norway are open now. Recruiting first, the newest first:

16 more — sign in →

All 22 open studies →

A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →

Who these studies take

Of the 109 Obesity, Morbid studies recruiting now, 21 (19%) set no upper age limit and 83 (76%) stop at 75 or younger; 8 take children under 18; 9 take healthy volunteers.

This study: 20 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Obesity, Morbid with a site in Norway, or all of them as a file.
02

Study summary

This study will compare two bariatric surgical interventions in terms of weight loss, gastroesophageal reflux, and effects on obesity-related comorbid conditions in morbidly obese patients.

Read the detailed description

Sleeve gastrectomy is an established therapeutic option for morbidly obese patients without preexisting gastroesophageal reflux disease. The novel single anastomosis sleeve ileal bypass (SASI) procedure is already introduced in Norway at a private high-volume bariatric hospital. The purpose of this study is to evaluate the effects of SASI in comparison to an established bariatric procedure, i.e. sleeve gastrectomy. The primary end point is 2-year changes in BMI after sleeve gastrectomy and SASI.

03

Conditions studied

  • Obesity, Morbid

Browse trials for

Keywords

  • procedure: sleeve gastrectomy
  • bariatric surgery
  • procedure: single anastomosis sleeve ileal bypass
04

Who can participate

Ages eligible
20 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Morbid obesity at referral for bariatric surgery (i.e. a body-mass index [] of ≥35 kg/m2 with obesity-related comorbid conditions or ≥40 kg/m2 with or without such comorbidities).
  2. Age 20-60 years.
  3. Previous failed attempts of weight loss.
  4. Norwegian speaking patients.

Exclusion criteria

Exclusion Criteria:

  1. ≥55 kg/m2.
  2. A history of major abdominal or bariatric surgery (excluding appendectomy, cholecystectomy, and sectio).
  3. Established disabling cardiopulmonary disease, ongoing treatment for cancer, long-term use, and conditions believed to be associated with poor adherence after surgery.
  4. Previous or current gastroesophageal reflux symptoms with daily use of antireflux medication. Patients are also excluded if preoperative manometry identifies a hiatal hernia (≥4cm in axial length) or if preoperative upper endoscopy identifies esophagitis grade C or D (LA classification), peptic stricture, Barrett's esophagus, or esophageal carcinoma.
  5. Achalasia
  6. Pregnancy.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
220 participants (estimated)

Study arms

  • Experimental
    Single anastomosis sleeve ileal bypass

    A Single anastomosis sleeve ileal bypass procedure is performed.

    Procedure: Single anastomosis sleeve ileal bypass

  • Active comparator
    Sleeve gastrectomy

    A sleeve gastrectomy procedure is performed.

    Procedure: Sleeve gastrectomy

Interventions

  • ProcedureSingle anastomosis sleeve ileal bypass

    The abdominal cavity is entered directly (visual trocar) with or without the use of Verres needle. A 6-port set up and a liver retractor is utilized. A sleeve gastrectomy is performed as described below, but division of the stomach starts 6 cm proximal to the pylorus. The small bowel is measured 300cm from the ileocecal valve, with the small bowel stretched and markers placed on the graspers, and connected to the antrum of the stomach with a 45mm stapler. The anastomosis is positioned slightly ventral on the antrum. A 12 mm port positioned left to the midline is used for introduction of the stapler, which is directed distally from the patient's left to right side. 3.0 cm of 45 mm stapler is used the anastomosis; completed with a 2-0 PDS running suture. The biliopancreatic limb is anchored to the sleeve 4 cm proximal to the anastomosis (non-resorbable V-loc 3-0). Fascia defect is closed for the port where the specimen is extracted. The mesenteric defect is not closed.

    Also known as: SASI

  • ProcedureSleeve gastrectomy

    In the laparoscopic sleeve gastrectomy, the abdominal cavity is entered directly with a visual trocar with or without the use of Verres needle. The set up includes a total of 5 ports. The Natanson liver retractor is utilized. The greater omentum is separated from the major side of the stomach from the pylorus to the angle of His. The left crus is visualized and the hiatus is inspected for the presence of hernia. A 36 French bougie is introduced and the stomach is divided along this from 4-5cm proximal to the pylorus to 1cm lateral to the angle of His using two purple cartridges (Medtronic Tri-Staple™ technology) followed by beige 60mm cartridges to the angle of His, 1 cm lateral to the esophagus. The sleeve is tested for leaks with instillation of 50ml methylene blue in the tube. The fascia defect is closed with suture for the port site where the specimen is extracted.

06

What researchers measure

Primary outcomes

  1. Changes in body-mass index (BMI)

    Weight in kilograms divided by the square of the height in meters after sleeve gastrectomy and SASI.

    Time frame: 2 year

Secondary outcomes

  1. Change in prevalence of esophagitis.

    Changes in the prevalence of esophagitis as evaluated by upper endoscopy.

    Time frame: 2 year

  2. Change in prevalence of gastroesophageal reflux disease.

    Changes in the prevalence of gastroesophageal reflux disease as evaluated by 24-hour pH measurements.

    Time frame: 2 year

  3. Complications

    Complications during surgery, postoperative complications (within 6 weeks \[100 days for deaths\]) as defined by the Accordion severity grading system and long-term complications.

    Time frame: 6 weeks (100 days for deaths), 2 year, 5 year

  4. Obesity-related comorbid conditions.

    Changes in obesity-related comorbid conditions.

    Time frame: 2 year, 5 year

  5. Vitamin concentrations

    Changes in vitamin levels (A, B1, B6, B9, B12, C, D, K).

    Time frame: 2 year, 5 year

  6. Health-related quality of life

    The RAND 36-Item Short Form Health Survery is a self-reporting questionnaire. Items are scored from 0 (lowest score) to 100 (highest possible score).

    Time frame: 2 year, 5 year

  7. Obesity-related symptoms

    Obesity-related Problem scale

    Time frame: 2 year, 5 year

  8. Gastrointestinal symptoms

    GSRS

    Time frame: 2 year, 5 year

  9. Gastroesophageal reflux disease symptoms

    GERDq

    Time frame: 2 year, 5 year

  10. Bowel habits

    Bowel habit questionnaire

    Time frame: 2 year, 5 year

  11. Revisional surgery

    Revisional surgery rates in the two groups.

    Time frame: 2 year, 5 year

  12. Long-term changes in BMI

    BMI (weight in kilograms divided by the square of the height in meters) after sleeve gastrectomy and SASI.

    Time frame: 5 years

  13. Body composition

    Changes in percentage fat mass and lean mass; percentage change in bone mineral density in lumbar spine (L1-L4), femoral neck, and total hip as assessed by DEXA scan.

    Time frame: 2 years

07

Study locations

2 of 2 sites recruiting
  • The Morbid Obesity Center, Vestfold Hospital Trust
    Tønsberg, Vestfold 3103, Norway
    Recruiting
    • Marius Svanevik, MD, PhD · Contact
  • Oslo University Hospital
    Oslo, 4950, Norway
    Recruiting
    • Helene M Haug, MD · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Dec 2028, 70 months after the start.

Of 273 non-industry interventional studies with no phase under Obesity, Morbid, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 48. This study's planned 70 months is above that.

Counting every sponsor, half of 285 studies reached it within 25 months; a quarter within 11 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2022
First posted
Nov 10, 2022
StartActual
Feb 17, 2023
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2031
Last update
May 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05611697
Responsible party
Torgeir Søvik (Principal Investigator, Oslo University Hospital) — Principal investigator
First posted
Nov 10, 2022
Start date
Feb 17, 2023
Primary completion
Dec 2028 (estimated)
Completion
Dec 2031 (estimated)
Last update
May 18, 2026

Study contacts

Helene M Haug, MD
Contact
b31831@ous-hf.no
+47 22 11 80 80
Torgeir T Søvik, MD, PhD
principal investigator · Oslo University Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion